Simple blood test may spot heart risk in scleroderma patients
NCT ID NCT07209644
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at whether a substance in the blood called catestatin is linked to heart and blood vessel problems in people with systemic sclerosis (scleroderma). Researchers will measure catestatin levels in 70 patients and compare them to healthy people. The goal is to see if catestatin could be used as a marker to track disease severity.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could point toward a simple blood test to monitor disease activity and heart risk in systemic sclerosis patients.
- What could go wrong
- This is an early observational study with only 70 participants, so results may not apply to everyone. It looks for a link, not a treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immune clues in the blood may foretell heart trouble
- Blood particles may reveal hidden clues to scleroderma complications
- Could a simple injection dissolve painful calcium lumps in rare diseases?
- Finger injections aim to loosen stiff hands in scleroderma
- Continued anifrolumab treatment studied for lupus and related diseases
- Blood thinner may stop autoimmune disease before it starts